JAN 0 7 2004

FORM PTO-1449 (MODIFUED)

ATTORNEY DOCKET NO. | APPLICATION NO. P24,376-A USA

09/743,173

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE APPLICANT **STATEMENT** 

M. Seves , D. O'Mahony, D. Page...

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE January 14, 2002 GROUP ART UNIT 1614-

1635

U.S. Department of Commerce Patent and Trademark Office

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	DATE	COUNTRY
	AN	0 890 362 A	01/13/1999	EP
0	AO	95 26718 A	10/12/1995	wo
	AP	00 02601 A	01/20/2000	wo
	AQ	99 60167 A	11/25/1999	wo
7	AR	99 01579 A	01/14/1999	wo
$\mathcal{I}$				

## OTHER PUBLICATIONS

X	ВА	Akhtar, "Antisense Technology: Selection and Delivery of Optimally Acting Antisense Oligonucleotides," J. Drug Targeting, 5(4):225-234 (1998)
	ВВ	Bennett et al., "DNA Binding to Human Leukocytes," J. Clin. Invest., 76:2182-2190 (1985)
	ВС	Chin et al., "Rapid Nuclear Accumulation of Injected Oligodeoxyribonucleotides," New Biol. 9:1091-1100 (1990)
	BD	Loke et al., "Characterization of Oligonucleotide Transport into Living Cells," Proc. Natl. Acad. Sci. U.S.A., 86:3474-3478 (1989)
	BE	Stein et al., "Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: characterization and preliminary kinetics of cellular uptake," Gene, 72:333-341(1988)
	BF	Stein, "Phosphorothioate Antisense Oligodeoxyribonucleotides: Questions of Specificity," Trends Biotechnology, 14(5):147-49 (1996)
	BG	Yakubov et al., "Mechanism of Oligonucleotide Uptake by Cells: Involvement of Specific Receptors," Proc. Natl. Acad. Sci. U.S.A., 86:6454-6458 (1989)
X	ВН	Crooke et al., "In Vitro Pharmacokinetics of Phosphorothioate Antisense Olidonucleotides," J. Pharmacology and Exp. Theraputics., 275(1):462-473 (1995)

EXAMINER	AM	DATE CONSIDERED
		citation is in conformance with MPEP 609; Draw line include copy of this form with next communication to  Sheet1 of1
		January 5, 2004